I attended the Synairgen AGM last Friday (June 22nd 2018), which was held at the offices of Fladgate LLP, 16 Great Queen Street, London.
For investors who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at…
Click here for the complete AGM report if you are a full member of ShareSoc, as these reports are exclusive to our full members. The above is only an introduction to the full report, which contains much more information. Further information about access to our AGM reports can be found here.